- Home
- / Blueprint Medicines
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Blueprint Medicines financials data including stock price, CreditSafe score, income statement, balance sheet, cash flow, and acquistions and subsidiaries.
Stock Price
$83.4
2024-10-29
Market Capitalization
$5.3 B
2024-10-29
Revenue
$508.8 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|
| Revenue | 180.1M | 204.0M | 249.4M | 508.8M |
| Revenue growth, % | -77.3% | |||
| Cost of goods sold | 17.9M | 17.8M | 8.5M | 20.2M |
| Gross profit | 162.1M | 186.2M | 240.8M | 488.7M |
| Gross profit margin, % | 90.0% | 96.0% | ||
| General and administrative expense | 195.3M | 237.4M | 295.1M | 359.3M |
| Operating expense total | 804.1M | 723.7M | 727.1M | 731.8M |
| Interest income | 2.4M | |||
| Interest expense | 16.8M | 18.8M | 28.2M | |
| Pre tax profit | (641.1M) | (552.3M) | (506.0M) | (65.9M) |
| Income tax expense | 3.0M | 5.2M | 968.0K | 1.2M |
| Net Income | (644.1M) | (557.5M) | (507.0M) | (67.1M) |
| EPS | (11.0) | (9.0) | (8.0) | (1.1) |
Acquisitions & Subsidiaries
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content only available in Craft’s Intelligence Portal View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |